Research Article
Construction of a Cuproptosis-Related lncRNA Prognostic Model for Bladder Urothelial Carcinoma and Screening of Potential Drugs
Table 3
Clinical statistical analysis of groups.
| | Covariates | Type | Total | Test | Train | -value |
| | Age (years) | ≤65 | 159 (39.36%) | 75 (37.13%) | 84 (41.58%) | 0.4152 | | >65 | 245 (60.64%) | 127 (62.87%) | 118 (58.42%) | | Gender | Female | 106 (26.24%) | 49 (24.26%) | 57 (28.22%) | 0.4286 | | Male | 298 (73.76%) | 153 (75.74%) | 145 (71.78%) | | Grades | High grade | 381 (94.31%) | 193 (95.54%) | 188 (93.07%) | 0.4841 | | Low grade | 20 (4.95%) | 8 (3.96%) | 12 (5.94%) | | Unknown | 3 (0.74%) | 1 (0.5%) | 2 (0.99%) | | Stages | Stage I | 2 (0.5%) | 2 (0.99%) | 0 (0%) | 0.4932 | | Stage II | 128 (31.68%) | 61 (30.2%) | 67 (33.17%) | | Stage III | 140 (34.65%) | 70 (34.65%) | 70 (34.65%) | | Stage IV | 132 (32.67%) | 68 (33.66%) | 64 (31.68%) | | Unknown | 2 (0.5%) | 1 (0.5%) | 1 (0.5%) | | T | T0 | 1 (0.25%) | 1 (0.5%) | 0 (0%) | 0.8389 | | T1 | 3 (0.74%) | 2 (0.99%) | 1 (0.5%) | | T2 | 117 (28.96%) | 57 (28.22%) | 60 (29.7%) | | T3 | 193 (47.77%) | 97 (48.02%) | 96 (47.52%) | | T4 | 57 (14.11%) | 29 (14.36%) | 28 (13.86%) | | Unknown | 33 (8.17%) | 16 (7.92%) | 17 (8.42%) | | M | M0 | 194 (48.02%) | 98 (48.51%) | 96 (47.52%) | 1 | | M1 | 11 (2.72%) | 6 (2.97%) | 5 (2.48%) | | Unknown | 199 (49.26%) | 98 (48.51%) | 101 (50%) | | N | N0 | 235 (58.17%) | 115 (56.93%) | 120 (59.41%) | 0.926 | | N1 | 46 (11.39%) | 25 (12.38%) | 21 (10.4%) | | N2 | 75 (18.56%) | 38 (18.81%) | 37 (18.32%) | | N3 | 6 (1.49%) | 3 (1.49%) | 3 (1.49%) | | Unknown | 42 (10.4%) | 21 (10.4%) | 21 (10.4%) | |
|
|
